in, etc., have been identified. Yet published experimental evidence in support of the view of the nonexistence of a serum folate binder is sparse and rather inconclusive.
Metz et al. (1) in 1968 reported on folic acid binding by serum and milk and concluded that folate binding by serum was weak. Rothenberg (2) in a 1973 publication, citing work of Markkanen (3) ,
states that "the major fraction of folate in serum is not bound firmly to any protein . . . " Some of the radioassays developed for quantitative estimation of folate in serum (4) (5) (6) (7) rest on the concept that serum folate is readily available to be bound by the extraneous folate binders of the test system when serum samples are used without pretreatment to liberate the endogenous folates from the serum proteins. This direct approach to serum folate assay has recently Folate binding by human serum has also been investigated by others (11) (12) (13) (14) (15) (16) , but it has remained unresolved whether such binding by the serum of normal, healthy persons is only weak and nonspecific or if it is specific and so firm as to be considered physiologically significant. (17) , and in women who are pregnant or taking contraceptives (18) . Carl- son2 recently reported on encountering marked folate binding by the serum of some normal persons, a phenomenon which appeared to be "genetic in origin" and not associated with disease.
Thus, these studies seem to show that serum folate normally is only weakly bound, while binding of increased strength as well as capacity occurs only in special disease or genetic states. We believe that we have evidence to the contrary. We are presenting here results of a systematic investigation of the question of whether specific serum folate binders indeed exist or not and whether such binders are a normal constituent of human sera or if they are found only in a certain percentage of the population.
Our study indicates that (a) human serum normally contains a principle that binds folates, (b) the binding principle is specific for folates, and that (c) the binding reaction is reversible and hence of the mass-equilibrium type.
Materials
Normal sera were obtained from 99 healthy volunteers (laboratory employees). Venous blood was drawn into red-stoppered Vacutainers and after clotting, the serum was separated by centrifugation and stored at 4 #{176}C. The sera were used within 24 h.
Patient sera were obtained from 916 patients' blood samples chosen without conscious bias from those received by the clinical chemistry laboratory. Sample handling was as for the normal sera. Coleman and Bell) suspended in 100 ml of Tris buffer, mixed with an equal volume of Tris buffer containing 20 g of dextran per liter. Two volumes of this charcoal preparation were used to adsorb the unbound radioactivity from one volume of binding reaction mixture. At this volume ratio, less than 1 mm of time was required to complete adsorption.
The blank values remaining after adsorption of the label from buffer or albumin solutions without binder were of the order of 2-5% of the total radioactivity originally added. Additional adsorption, by increasing the time of exposure or amount of charcoal, did not lower the blank values. We should also like to emphasize that human or bovine albumin solutions when incubated with the label for periods of several hours did not bind any measurable amounts of the labeled material as the cpms remaining in buffer vis-a-vis albumin solutions (5 g/100 ml) after charcoal treatment were identical. For the dissociation study by addition of excess of unlabeled ligand, it was necessary to evaluate the charcoal adsorption of [3H]PGA in the presence of a 1000-fold excess of unlabeled PGA. It was found that 15 000 ng/ml of unlabeled PGA did not interfere with the adsorption of 15 ng/ml of [3H]PGA from water, saline, Trig buffer, human or bovine albumin (5 g/100 ml), or serum.
N-5-Forrnyltetrahydrofolic acid (Calcium Leucovorin; Lederle). Working dilutions were made in Tris buffer containing 50 mg of ascorbate per 100 ml, and used only on day of preparation. The radioactivity bound by each individual serum was converted into nano- Methotrexate. 4-Amino-N'#{176}-methylfolic acid, sodium salt (Lederle). Working dilutions were made in Tris buffer, and used only on day of preparation.
Sodium salicylate (Baker Chemical Co.). Working solution made in Tris buffer.
Sodium barbital (Merck). Working dilutions made
in Tris buffer.
5,5-Diphenylhydantoin
(Matheson, Coleman and Bell). Stock solutions of 100 mg/100 ml in ethanol. Working dilutions made from this stock in Tris buffer. The minute amounts of alcohol (1.5 mg/100 ml or less) introduced into the working dilutions from the stock solution are entirely negligible; as much as 1000 mg of alcohol in 100 ml of the reaction mixtures was without effect on the binding reactions.
Scintillant. 5 g of "PPO," 0.3 g of "POPOP" (both from Mallinckrodt Chemical Works), 100 ml of "BioSolv-BBS-2"
(Beckman Instruments), 1 liter of toluene.
Experiments and Results

. Association Reaction between Serum and [3H] PGA
To assess the requirements for incubation times, we studied the binding of [3H]PGA by serum as a function of time. Five milliliters of a pool of seven sera with high folate binding capacity were mixed with 7.5 ml of a solution containing 15 ng/ml of [3H}PGA and incubated at room temperature (22 #{176}C). After periods of time ranging from 1 to 60 mm, duplicate aliquots of 250 jzl of the incubation mixture were placed into test tubes, to which 0.5 ml of the er, and incubated for 15 mm at room temperature (22 #{176}C). Then, 500 l of charcoal were added, and after 1 mm the mixtures were centrifuged for 5 mm. The supernatarit fluid, yielding about 650 l, was decanted by thorough draining into 12 The results were plotted according to frequency distribution as shown in Figure 2 for the normal and patient sera, respectively.
Virtually all sera tested exhibited binding of [3H]PGA, although of greatly varying capacity.
Only three patients' sera gave values slightly less than the buffer "blanks," but these differences were well within the range of the experimental error (SD ±0.06 ng/ml). The distribution and the range of the binding capacities of the normal as well as of the patients' sera was essentially the same. The binding capacity of sera of a few persons who were sampled over a period ranging from several weeks to more than one year did not change substantially.
Specificity of Serum Binding Principle for Folate Derivatives
A pool of sera with medium binding capacities for [3H]PGA was used to study the relative affinities of folate derivatives and some nonfolate compounds for the binder in serum by a typical competitive binding reaction of the equilibrium type (21) . Aliquots of 100 l of the calibrating solutions were mixed with 100 sl of the [3H]PGA solution (3 ng/ml), then 100 sl of the serum pool were added and incubated at room temperature (22 #{176}C) for 30 mm. From the charcoal adsorption step on, the samples were then handled as described in the previous paragraph. The results, plotted in the manner of dose-response curves, are shown in Figure 3 . All folate derivatives tested were able to inhibit the binding [3HJPGA, but they differed considerably in their effectiveness. Diphenylhydantoin, salicylate, and barbituric acid failed to lower the [3HJPGA binding in the concentrations tested.
Competitive Binding of PGA and MTHFA by Sera with Various Binding Capacities
Ten individual sera were selected to represent the entire ranges of binding capacities as shown in Figure  2 . Competitive binding experiments including equilibrium as well as sequential saturation techniques (21, 22) were carried out with these sera, with use of PGA and MTHFA as the unlabeled analogs to inhibit the binding of [3HJPGA. Because of the high binding capacity of some of the sera, the amounts of labeled and unlabeled folate analogs to be added to each reaction tube were increased fivefold to allow for full saturation of the binders. For the equilibrium method, 500-id aliquots of the calibrating solutions (unlabeled analogs) were mixed with 100 jzl of [3H]PGA (15 ng/ml); 100 sl of serum was then added and the mixtures were incubated for 30 mm at room temperature. After treatment with 0.5 ml of charcoal and centrifugation, the supernatant fluid was decanted into 17 ml of scintillant for counting.
For the sequential saturation method, 500-al aliquots of the calibrating solutions were incubated with 100 il of serum for 30 mm; 100 zl of [3H]PGA (15 ng/ml) was then added and the mixtures were allowed to stand for a second incubation period of only 10 mm, after which the procedure was continued from the charcoal step on as in the equilibrium method. The results are shown in Figures 4-7 MTHFA was slower than with PGA, but the dissociation reaction proceeded with about the same velocity as that found for PGA.
Dissociation Reaction of [3H] PGA-Serum Complex
Dissociation of bound [3H]PGA from serum was studied by the charcoal adsorption technique as well as by the method of addition of excess of unlabeled ligand (22) . Five milliliters of a pool of sera with high folate binding capacity were mixed with 5 ml (50 ng) of [3H]PGA and incubated under a light-proof cover on a rotary shaker for 1 h to allow for saturation of the binder. The temperature under the cover was 30 #{176}C owing to the heat from the motor. For the dissociation by charcoal adsorption, 10 ml of charcoal were added to half (5 ml) of this incubation mixture and returned to the shaker to keep the charcoal in suspension. At time intervals ranging from 1 mm to 22 h, 1-mI aliquots were removed, centrifuged, and the radioactivity of the supernatant fluids was determined. For the dissociation study of "addition of excess," 1 ml of a solution of PGA containing 50 000 ng/ml was added to the other half of the original incubation mixture and returned to the shaker. At time intervals ranging from 1 mm to 22 h, aliquots of 250 l were removed, treated with 0.5 ml of charcoal for 1 mm, centrifuged, and the radioactivity of the supernatant fluids was determined.
Because of the volume differences between the two test series, the results were expressed in percent of the radioactivity bound at the respective 1-mm points. The results are shown in Figure 8 . The dissociation curves obtained by both techniques are similar and indicate that [3H]PGA when bound to serum will dissociate under both experimental conditions with a more rapid rate during the initial hours of the experiment.
The association and dissociation reactions of MTHFA and serum binder were investigated by techniques analogous to those described for MTHFA and milk folate binder (22) . The association with
Discussion
We believe that in the foregoing experiments we have produced evidence that human serum normally contains a principle that is capable of specifically binding folate derivatives.
The screening of 99 normal volunteers' and 916 patients' sera revealed that essentially all sera tested that the binding of folate by serum is a reversible reaction of the equilibrium type. The dissociation graph of Figure 8 shows that approximately 20% of the total [3H]PGA initially bound will dissociate within 15 mm. Thus, [3HJPGA, when added to serum, will be able to exchange with a fraction of the bound endogenous folate while the latter spontaneously dissociates from its binder. Accordingly, some of the [3H]PGA will become bound during a few minutes of incubation, even though the binder may have been nearly fully saturated with endogenous folate at the beginning of the incubation period. If the apparent low binding capacity for [3H]PGA that is observed in most sera is explained on this basis, then the data of Figure 2 should be interpreted to indicate that the folate binder in most sera is fully or nearly fully saturated.
In fact, it is conceivable that some sera may contain a total folate concentration exceeding the binding capacity of the binder, so that a significant fraction of the folate will be free. Yet, when [3HJPGA is added to such a system, some of it will CLINICALCHEMISTRY, Vol. 20, No. 10, 1974 become bound through dissociation and exchange of the bound endogenous folate fraction.
Our studies of the association and dissociation of [3HJPGA and MTHFA with serum demonstrate that the reaction between folates and serum binder is reversible. Therefore, a mass equilibrium must exist between bound and free folate in circulating plasma whether or not the total folate concentration (free and bound) exceeds the binding capacity of the binder. The distribution of the total serum folate between bound and free fractions presently cannot be meaningfully estimated, because neither the number of different binders involved nor their respective relative affinity constants are known.
The competitive binding studies shown in Figure 3 are substantial evidence that the binder in serum is specific for folate derivatives.
Specificity here is defined as high affinity of the binder for the ligand in question. The in vitro concentrations tested in the competitive inhibition experiments were in the physiologic range, and it is therefore reasonable to assume that the binder is also effective in vivo. Nonfolate compounds (barbiturate, diphenylhydantoin, and a reflection of the number of available free binding sites, or are due to differences in the affinity constants of the binders from one serum to another.
The folate binding principle in serum in all probability consists of a protein; we were able to abolish or diminish the folate binding of serum when denaturing the serum proteins by heating, acid, alkali, and (or) alcohol. The binding principle is nondialyzable (11) and nonultrafiltrable (12) . Labeled folic acid migrates with serum proteins on electrophoresis (12) or chromatography (13) (14) (15) (16) , but the extensive dissociation of the folate-serum binder complex that certainly occurs during these procedures may result in a folate migration or elution pattern not representative of the in vivo distribution of bound folate. Calculation of dissociation constants from the dissociation experiments (Figure 8 ) did not lead to a single value; the dissociation velocity was found to decrease considerably with the duration of the experiment. This would support the assumption of more than one binder with differing affinities; those with lower affinities, dissociating more rapidly, produced the initial, steep portion of the dissociation curve, while those with higher affinities, dissociating more slowly, produced the later, flatter portion. The origin of the binder presently remains speculation.
It should be considered, however, that perhaps a fraction of the binder may derive from leukocytes or even erythrocytes, particularly in view of the observations that in chronic myelogenous leukemia (1 7) and in pregnancy (18) folate binding increases in leukocytes as well as in serum.
Because of the great variability of the binding capacities of the various sera, we screened a large number of samples in the expectation of discerning a possible relationship between the occurrence of the binder in serum and certain disease states. However, we were unable to confirm this expectation as we did not find a clearly recognizable correlation of the magnitude of the serum folate binding capacity with the clinical diagnoses of the patients. However, there appeared to be a trend toward higher binding capacities in the sera from the volunteer women who were taking contraceptives, which is in agreement with the report by DaCosta and Rothenberg (18 and that the degree of binder saturation with the endogenous folate in persons not folate-deficient may range from partial to nearly complete saturation. An increase of folate binding by serum in folate deflcienby the serum after charcoal treatment-from the counts bound in the assay samples constitutes only a partial correction for the interference caused by the serum folate binders. cy was reported by Waxman and Schreiber (7, 16) .
We have also found that the binding capacity of sera for [3H]PGA increases when it is aged at room temperature, a phenomenon also seen by others (10) . This is readily explained on the basis of the known instability of MTHFA in the absence of sufficient reducing agents. Presumably, MTHFA spontaneously decays into compounds that do not bind to the specific binding sites on the serum folate binder. In other words, the binder is more stable than is its hgand.
We should also like to discuss the problem of the interference created by the serum folate binder when competitive binding assays of serum folate are attempted.
If serum is used directly in such an assay, (4-7) without separation of the folate from the serum binder, one wonders what is actually measured. In the case of a sequential saturation technique (5 ), the following considerations would apply: when the serum to be assayed is first mixed with the particular binder (obtained from milk, kidney, etc.), the latter will initially rapidly bind the free fraction of the serum folates. The bound serum fraction will become available for binding by the specific binder only as it undergoes spontaneous but relatively slow dissociation from the serum binder. The distribution of the total serum folate between the two binders will thus depend largely on the length of the incubation time of this first test phase as well as the relative quantities of the binders involved. When the labeled folate is added in the second phase, it will bind to the unsaturated sites of the serum binder as well as those of the milk or kidney binder. In the first step, too littie of the serum folate becomes bound to the milk binder. In the second step, too much labeled folate becomes bound to both binders. Thus, both these processes tend to lead to a spurious lowering of the final assay values. Indeed, considerably lower serum folate values are reported for such radioassays than for microbiologic methods.
In the case of equilibrium techniques (4, 6, 7) , similar considerations apply, except that incubation of the system's components is simultaneous and that the label as well as the endogenous serum folate will distribute themselves between serum and milk or kidney binders. This distribution will depend on the unsaturated fraction of the serum binder, the total concentration of the serum binder, the length of incubation, the relative affinities of these binders, etc. The result again will be assay values that are too low.
It is clear that in either case, serum folate must be separated from its binder before competitive binding assays are used. In view of the above considerations, it should be emphasized that the practice of subtracting the "serum blanks" (7, 9)-i.e., the counts bound
